美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

SCILEX HOLDING COMPANY C/WTS 10/11/2027(TO PUR COM)

0.2500

-0.0474-15.94%

成交量：2.63萬

成交額：6,347.55

市值：173.89萬

市盈率：- -

高：0.3000

開：0.3000

低：0.2100

收：0.2974

52周最高：0.6500

52周最低：0.0375

股本：695.57萬

流通股本：695.57萬

量比：0.85

換手率：0.38%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：-59.70%

市淨率：-0.01

市盈率(LYR):- -

資料載入中...

總覽公司新聞公告

公司資料

公司名字：

SCILEX HOLDING COMPANY C/WTS 10/11/2027(TO PUR COM)

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.scilexholding.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Scilex Holding Company於2019年2月在特拉華州成立。該公司是一家創新型創收公司，專註於收購、開發和商業化用於治療急性和慢性疼痛的非阿片類藥物管理產品。該公司認為，該公司創新的非阿片類藥物產品組合有潛力提供有效的疼痛管理療法，可以對患者的生活產生變革性影響。該公司以非阿片類藥物療法治療急性和慢性疼痛患者的高未滿足需求和大市場機會的適應症為目標，致力於推進和改善患者預后。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/SCLXW/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SCLXW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SCLXW\",,,,,undefined,":{"symbol":"SCLXW","market":"US","secType":"STK","nameCN":"SCILEX HOLDING COMPANY C/WTS 10/11/2027(TO PUR COM)","latestPrice":0.25,"timestamp":1762376400000,"preClose":0.2974,"halted":0,"volume":26294,"delay":0,"floatShares":6955697,"shares":6955697,"eps":0,"marketStatus":"已收盤","change":-0.0474,"latestTime":"11-05 16:00:00 EST","open":0.3,"high":0.3,"low":0.21,"amount":6347.5545,"amplitude":0.302623,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1762419600000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":0.2974,"volumeRatio":0.845825},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SCLXW\",,,,,undefined,":{"symbol":"SCLXW","floatShares":6955697,"roa":"-59.70%","roe":"--","lyrEps":0,"volumeRatio":0.845825,"shares":6955697,"dividePrice":0,"high":0.3,"amplitude":0.302623,"preClose":0.2974,"low":0.21,"week52Low":0.0375,"pbRate":"-0.01","psRate":"0.03","week52High":0.65,"institutionHeld":0,"latestPrice":0.25,"eps":0,"divideRate":0,"volume":26294,"delay":0,"ttmEps":0,"open":0.3,"prevYearClose":0.21,"prevWeekClose":0.25,"prevMonthClose":0.25,"prevQuarterClose":0.2401,"fiveDayClose":0.2625,"twentyDayClose":0.1513,"sixtyDayClose":0.5},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SCLXW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SCLXW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SCLXW\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.scilexholding.com","stockEarnings":[{"period":"1week","weight":0.487},{"period":"1month","weight":0.5653},{"period":"3month","weight":-0.3942},{"period":"6month","weight":3.0745},{"period":"1year","weight":0.022},{"period":"ytd","weight":0.4162}],"compareEarnings":[{"period":"1week","weight":-0.0172},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0671},{"period":"6month","weight":0.195},{"period":"1year","weight":0.185},{"period":"ytd","weight":0.1521}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Scilex Holding Company於2019年2月在特拉華州成立。該公司是一家創新型創收公司，專註於收購、開發和商業化用於治療急性和慢性疼痛的非阿片類藥物管理產品。該公司認為，該公司創新的非阿片類藥物產品組合有潛力提供有效的疼痛管理療法，可以對患者的生活產生變革性影響。該公司以非阿片類藥物療法治療急性和慢性疼痛患者的高未滿足需求和大市場機會的適應症為目標，致力於推進和改善患者預后。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":1.614312},{"month":2,"riseRate":0.25,"avgChangeRate":-0.175218},{"month":3,"riseRate":0.5,"avgChangeRate":0.000965},{"month":4,"riseRate":0.6,"avgChangeRate":0.094252},{"month":5,"riseRate":0.2,"avgChangeRate":-0.09574},{"month":6,"riseRate":0.6,"avgChangeRate":0.094055},{"month":7,"riseRate":0.8,"avgChangeRate":0.891221},{"month":8,"riseRate":0.2,"avgChangeRate":-0.142129},{"month":9,"riseRate":0.2,"avgChangeRate":-0.220439},{"month":10,"riseRate":0.8,"avgChangeRate":0.142407},{"month":11,"riseRate":0.8,"avgChangeRate":0.124468},{"month":12,"riseRate":0,"avgChangeRate":-0.22613}],"exchange":"NASDAQ","name":"SCILEX HOLDING COMPANY C/WTS 10/11/2027(TO PUR COM)","nameEN":"SCILEX HOLDING COMPANY C/WTS 10/11/2027(TO PUR COM)"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"SCLXW\",market:\"US\",,,undefined,":null}}